Upendra Nagaich
Amity Institute of Pharmacy,India
Title: Modernism in Therapeutic Proteins Production
Biography
Biography: Upendra Nagaich
Abstract
Therapeutic recombinant proteins are the most significant and swiftly expanding sector of the biopharmaceutical market. The promising commerce of therapeutic proteins have remarked a standard change with enhanced efficacy, greater safety, and reduced immunogenicity approaches from the combination of clinical, scientific, technological and commercial drivers that have identified unmet needs. These proteins can be grouped into molecular types which fundamentally includes anticoagulants, blood factors, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytic. Recombinant proteins are manufactured in bacteria, yeast, filamentous fungi, insect cells, mammalian cells, transgenic animals, and transgenic plants. Major production of 39 percent recombinant proteins is achieved by E. coli, 35 per cent by CHO cells, 15 per cent by yeasts, 10 per cent by other mammalian systems. Recombinant Protein drugs have revolutionized the prospects for the treatment of many types of cancer and rheumatic conditions. The foremost approach which has been adopted for the production of second generation protein products comprises reformulation, pegylation and other forms of modification, or the creation of analogues with different amino acid structures. Now the long established pharmaceutical manufacturers will have to spotlight for these future biologic products. It will be a great challenge to bring about the innovation, instead of renovation, to achieve pure, safe, high efficacy, cost effective and high yielding recombinant human therapeutic proteins with excellence.